An inflammatory pathomechanism for Parkinson's disease?

Current Medicinal Chemistry
Christophe Wersinger, Anita Sidhu

Abstract

Parkinson's disease (PD) is a slowly progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNpc), striatal dopamine deficiency and appearance of Lewy bodies. Inflammatory and immune, or even autoimmune, stigmata, have been described in post-mortem brains of PD patients. Although disputed in humans, a reactive astrocytosis and a lymphocytic infiltration in the SNpc have been observed in animal models of PD, which need further examination. This review summarizes the current knowledge on brain inflammation in humans with PD, and how inflammation and/or (auto)immune reactions within the SNpc could be linked to other pathophysiological mechanisms that have been hypothesized for the etiology of PD, such as oxidative stress, exposure to neurotoxins, and post-infectious or post-traumatic injuries. In particular, we discuss how microglial cells could be activated during the course of PD, and present a new hypothesis that PD-linked protein (alpha-synuclein, in particular) aggregates could be implicated in their activation, to induce a chronic and sustained inflammation involved in the progression, at least, of the disease. The current status of anti-inflammatory ag...Continue Reading

Citations

Oct 13, 2009·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Jae-Kyung LeeMalú G Tansey
Aug 18, 2009·Journal of Molecular Neuroscience : MN·Maryka QuikMichael Yeluashvili
May 13, 2009·Journal of Proteome Research·Ashley D ReynoldsHoward E Gendelman
Sep 13, 2007·The Neurologist·Linda L WerlingUrsula Calef
Jul 4, 2012·Journal of Neuroinflammation·Hyejin JeonKyoungho Suk
Feb 14, 2009·Neurochemical Research·Kerly Wollmeister HofmannCarlos R M Rieder
Nov 28, 2014·Molecular Neurobiology·Arvind Kumar ShuklaMohana Krishna Reddy Mudiam
Dec 15, 2015·BMC Medicine·Amos D Korczyn, Sharon Hassin-Baer
Feb 17, 2017·Parkinsonism & Related Disorders·Arun Parashar, Malairaman Udayabanu
Jun 9, 2018·The International Journal of Neuroscience·Asmat Ullah KhanRida Zainab
May 15, 2007·Current Opinion in Neurology·Andis KlegerisPatrick L McGeer
Nov 27, 2007·Journal of Neurochemistry·Ashley D ReynoldsHoward E Gendelman
Aug 2, 2008·Journal of Cellular and Molecular Medicine·Cintia RoodveldtChristopher M Dobson
Jun 4, 2010·Expert Review of Neurotherapeutics·W Michael CaudleJing Zhang
Oct 9, 2007·Brain Pathology·Jacqueline N Crawley
Sep 13, 2014·Molecular Medicine Reports·Junqiang YanGanqin Du
Mar 26, 2008·Neurochemical Research·Rebecca L MillerAlbert Y Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.

Related Papers

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Sen QiaoJing-hua Jin
Antioxidants & Redox Signaling
Terina N Martinez, J Timothy Greenamyre
Antioxidants & Redox Signaling
Aracely Garcia-GarciaRodrigo Franco
© 2021 Meta ULC. All rights reserved